Abstract
Relevance: Cancer is the second leading cause of death globally and is expected to be responsible for approximately 19.3 million
 new cases and 10 million deaths in 2022. With an unprecedented understanding of the molecular pathways that drive the development
 and progression of human cancers, novel targeted therapies have become an exciting new development for anticancer medicine. These
 targeted therapies, also known as biologic therapies, have become a primary treatment modality by blocking the growth of cancer cells
 by specifically targeting molecules required for cell growth and tumorigenesis. However, due to their specificity, these new therapies are
 expected to have better efficacy and limited adverse side effects than other treatment options, including hormonal and chemotherapy.
 The study aimed to present an overview of the advantages and prospects of targeted therapy in oncological practice.
 Methods: The search was carried out in the following databases: Scopus, Medline, Cochrane, PubMed, and Science Direct for 2016-
 2021. Sources were searched for the following keywords: clinical trials, immunotherapy, monoclonal antibodies, small molecular weight
 inhibitors, and targeted therapy.
 Results: This review explores the clinical development, successes, and challenges facing targeted anticancer therapies, including small
 molecule inhibitors and antibody-targeted therapies. The authors describe targeted therapies to epidermal growth factor receptor, vascular
 endothelial growth factor, human epidermal growth factor receptor 2, anaplastic lymphoma kinase, BRAF, T-cell mediated immune response
 inhibitors, cytotoxic T-lymphocyte-associated protein 4, and programmed cell death protein-1/PD-1 ligand.
 Conclusion: Over the past decade, there have been significant changes in cancer treatment, including targeted therapy, which has
 become more common. However, targeted drugs show low activity in monotherapy. In addition, the selection of patients for targeted
 therapy remains a difficult task since there are not enough reliable biomarkers to predict the action of most targeted agents. Therefore, it
 requires a deeper study of molecular biology, namely signaling pathways that determine the pathogenesis of cancers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
